文献速递白血病

急性髓系白血病中新型CDK9复合物的鉴定与靶向

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
PubMed 文献 · Blood · 2018-12-26

研究通过蛋白质组学分析发现CDK9是mTOR复合物支架蛋白mLST8的新型结合伙伴,在胞质和胞核形成不同的mTOR样(CTOR)复合物。胞核CTORC1促进白血病生成相关基因转录,胞质CTORC2通过磷酸化LARP1和rpS6控制mRNA翻译。药理学靶向CTORC复合物可抑制体外原始人AML祖细胞生长,并在体内AML异种移植中引发强效抗白血病反应。

要点

  • CDK9是mTOR复合物支架蛋白mLST8的新型结合伙伴,形成胞质和胞核CTOR复合物。
  • 胞核CTORC1结合RAPTOR和mLST8促进白血病生成相关基因转录。
  • 胞质CTORC2结合RICTOR、SIN1和mLST8通过磷酸化LARP1和rpS6控制mRNA翻译。

核心结论

  • CDK9存在于胞质和胞核中独特的mTOR样(CTOR)复合物中,药理学靶向CTORC复合物可抑制体外原始人AML祖细胞生长并在体内AML异种移植中引发强效抗白血病反应。

研究设计与样本

  • 研究通过蛋白质组学分析寻找mTOR复合物的独特相互作用因子,并开展体外和体内功能验证。

主要发现

  • CDK9被鉴定为mTOR复合物支架蛋白mLST8的新型结合伙伴。
  • 胞核中CDK9与RAPTOR和mLST8结合形成CTORC1,促进白血病生成相关基因转录。
  • 胞质中CDK9与RICTOR、SIN1和mLST8结合形成CTORC2,通过磷酸化LARP1和rpS6控制信使RNA翻译。
  • 药理学靶向CTORC复合物可抑制体外原始人AML祖细胞生长,并在体内AML异种移植中引发强效抗白血病反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant activation of mTOR signaling in acute myeloid leukemia (AML) results in a survival advantage that promotes the malignant phenotype. To improve our understanding of factors that contribute to mammalian target of rapamycin (mTOR) signaling activation and identify novel therapeutic targets, we searched for unique interactors of mTOR complexes through proteomics analyses. We identify cyclin dependent kinase 9 (CDK9) as a novel binding partner of the mTOR complex scaffold protein, mLST8. Our studies demonstrate that CDK9 is present in distinct mTOR-like (CTOR) complexes in the cytoplasm and nucleus. In the nucleus, CDK9 binds to RAPTOR and mLST8, forming CTORC1, to promote transcription of genes important for leukemogenesis. In the cytoplasm, CDK9 binds to RICTOR, SIN1, and mLST8, forming CTORC2, and controls messenger RNA (mRNA) translation through phosphorylation of LARP1 and rpS6. Pharmacological targeting of CTORC complexes results in suppression of growth of primitive human AML progenitors in vitro and elicits strong antileukemic responses in AML xenografts in vivo.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Beauchamp EM, Abedin SM, Radecki SG, et al. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood. 2018. PMID: 30587525. doi:10.1182/blood-2018-08-870089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。